|
|
|
|
|
Scientific Advisory Board
The scientific advisory board at Monogram is made up of renowned leaders in the fields of HIV, oncology and serious diseases. Based on their diverse qualifications, each of these individuals provides a unique perspective on the challenges and trends in the management of these diseases.
Carlos L. Arteaga, MD is Professor of Medicine and Cancer Biology and Director of the Breast Cancer Research Program of the Vanderbilt-Ingram Cancer Center at Vanderbilt University School of Medicine. Professor Arteaga's research focuses on the role of growth factor receptors, such as the EGF receptor, erb-B2 and TGF-beta receptors in the progression of breast cancer, as well as the development of anti-cancer molecular therapeutics.
Jose Baselga, MD is Professor of Medicine at the Universidad Autonoma de Barcelona and the Scientific Chairman of the Spanish Breast Cancer cooperative group SOLTI. Dr. Baselga's research interests are in clinical breast cancer and in the area of growth factor receptors and downstream molecules as targets for cancer therapy.
Stephen P. Goff, PhD is the Higgins Professor of Biochemistry and Molecular Biophysics at the College of Physicians and Surgeons of Columbia University, and an Investigator of the Howard Hughes Medical Institute. Dr. Goff received his PhD in biochemistry at Stanford University with Nobel Laureate Paul Berg, and his postdoctoral training in the laboratory of Nobel Laureate David Baltimore. Dr. Goff is a world-recognized expert on the replication of retroviruses, including HIV, and is widely known for his pioneering studies on the effects of mutations upon retroviruses.
David D. Ho, MD is the Scientific Director and Chief Executive Officer of the Aaron Diamond AIDS Research Center in New York and a Professor at The Rockefeller University. Dr. Ho received his MD from Harvard Medical School and his postdoctoral training at Massachusetts General Hospital and Harvard Medical School. Dr. Ho is world-renowned for his pioneering studies on the dynamics of HIV infection and its effects upon the human immune system, and is an expert on antiviral drug therapy for HIV.
Tony Hunter, PhD, is a Professor in the Molecular and Cell Biology Laboratory and Director of the Salk Institute Cancer Center. Professor Hunter's research focuses on how cell proliferation and division is regulated, and how mutations in genes that regulate these processes lead to cancer. His current efforts are aimed at elucidating how protein phosphorylation, ubiquitination, and SUMOylation events are used in cell proliferation and growth control, and cell cycle checkpoint activation in response to DNA damage.
Douglas D. Richman, MD is a Professor of Pathology and Medicine at the University of California, San Diego School of Medicine, and the Director of the Research Center for AIDS and HIV Infection at the San Diego VA Medical Center. Dr. Richman received his MD from Stanford University and his postdoctoral training at the National Institutes of Health and at Harvard Medical School. Dr. Richman is a leading AIDS clinical investigator, having directed the clinical trial resulting in the approval of AZT by the FDA; was the first to discover HIV drug resistance; and is considered by many to be the world's leading expert on HIV drug resistance.
Robert T. Schooley, MD is Professor and Head of the Division of Infectious Diseases of the University of California, San Diego. Dr. Schooley received his MD from Johns Hopkins University School of Medicine and his postdoctoral training at the NIH and Massachusetts General Hospital. He has served as Chair of the NIH's AIDS and Related Retrovirus Study Section and as Chair of the Executive Committee of the NIAID's AIDS Clinical Trials Group (ACTG). Dr. Schooley's interests are in the areas of viral pathogenesis and therapy.
|
|
 |
|
